ANGO stock sentiment todayAngioDynamics, Inc.
Sentiment verdict
Gossip first, financials second — COLD at 75% confidence.
Last updated · cached analysis, refreshes periodically
ANGO
AngioDynamics, Inc.A loss-making medical device player caught in a painful transition, struggling to translate promising clinical data into bottom-line stability.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ANGO. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by a disappointing Q1 earnings miss and a significant stock sell-off. While there is technical excitement surrounding the NanoKnife's efficacy in pancreatic cancer trials, investors are currently prioritizing fiscal discipline over long-term clinical potential.
- ·Q1 revenue and earnings miss
- ·8% single-day drop following financial updates
- ·Positive NanoKnife survival data (28 months vs 15 months)
- ·General market skepticism regarding med-tech profitability
Financial
ANGO is in a precarious financial position characterized by negative earnings and shrinking margins. The company has divested underperforming assets to focus on high-growth Med Tech (NanoKnife, Auryon), but the transition is burning cash, and the lack of a clear path to GAAP profitability weighs heavily on valuation.
- ·Negative EPS (recurring losses)
- ·Recent revenue miss relative to analyst expectations
- ·Market cap contraction below $500M
- ·High R&D spend relative to operating cash flow
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $655K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Continued cash burn during the Med Tech pivot
- ·Regulatory hurdles for expanded indications of NanoKnife
- ·Intense competition from larger, diversified medical device conglomerates
- ·Dependency on high-cost specialized sales forces
Peer temperature
How direct competitors stack up against ANGO right now.
- HOTPENPenumbra, Inc.
HOTTER — boasting robust double-digit revenue growth and consistent profitability in the vascular space where ANGO struggles.
See full analysis → - HOTBSXBoston Scientific
HOTTER — offers superior scale and a diversified portfolio that mitigates the clinical trial risks ANGO faces.
See full analysis → - NEUTRALMERKMerit Medical Systems
BETTER — maintains positive net income and a steadier balance sheet while competing in similar interventional oncology segments.
See full analysis →
- ANGO-22.0%
- PEN+0.2%
- BSX-3.8%
- MERK—
Analyst price target
Consensus average of 3 analysts · median 20.00
Source: StockAnalysis.com · updated 2026-10-22
Recent headlines
- Yahoo! Finance CanadaAngioDynamics, Inc. (ANGO) Stock Price, News, Quote & History
- Yahoo Finance AustraliaAngioDynamics, Inc. (ANGO) stock price, news, quote and history
- Simply Wall StAngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress
- BenzingaAngioDynamics Stock Is Falling Thursday: What's Going On?
- Stock Traders Daily(ANGO) Price Dynamics and Execution-Aware Positioning
- Stock TitanA pancreatic cancer study linked an electrical-pulse approach to 28 months’ median survival versus 15.
AI-generated analysis for informational purposes only. Not financial advice.